Search Within

Gynecologic Medicine Service

Formats
  1. Journal Article (1104)
  2. Meeting Abstract (902)
  3. Review (55)
  4. Book Section (46)
  5. Editorial (36)
  6. Guidelines (22)
  7. Correspondence (9)
  8. Miscellaneous (3)
  9. Research Letter (2)
  10. Book Whole (1)
Groups
  1. Solid Tumor Oncology Division (2180)
  2. Department of Medicine (2174)
  3. Gynecology Disease Management Team (1877)
  4. GDMT, Medicine (1859)
  5. Surgery (603)
  6. GDMT, Surgery (479)

More Groups

People
  1. Carol Aghajanian (615)
  2. Nadeem Abu-Rustum (292)
  3. Martee Hensley (290)
  4. Roisin O'Cearbhaill (273)
  5. Vicky Makker (269)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (75)
  2. 2024 (167)
  3. 2023 (171)
  4. 2022 (209)
  5. 2021 (163)
  6. 2020 (203)

More Years

Publications
  1. Journal of Clinical Oncology (458)
  2. Gynecologic Oncology (420)
  3. International Journal of Gynecological Cancer (161)
  4. Annals of Oncology (117)
  5. Clinical Cancer Research (71)
  6. Cancer Research (55)

More Publications

Publishers
  1. American Society of Clinical Oncology (498)
  2. Elsevier B.V. (446)
  3. Lippincott Williams & Wilkins (188)
  4. American Association for Cancer Research (173)
  5. Oxford University Press (144)
  6. Elsevier Inc. (128)

More Publishers

Results (2180)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Low-grade serous ovarian cancer: Expert consensus report on the state of the science
    Journal Article

    Grisham, R. N.; Slomovitz, B. M.; Andrews, N.; Banerjee, S.; Brown, J.; Carey, M. S.; Chui, H.; Coleman, R. L.; Fader, A. N.; Gaillard, S.; more...
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save
  • Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer
    Journal Article

    Lam, C.; Sarasohn, D.; Weigelt, B.; Zamarin, D.
    Gynecologic Oncology Reports (2023)

    Fulltext@MSK | Save
  • Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer
    Journal Article

    Zammarrelli, W. A. 3rd; Ma, W.; Espino, K.; Gordhandas, S.; Yeoshoua, E.; Ehmann, S.; Zhou, Q.; Iasonos, A.; Abu-Rustum, N. R.; Aghajanian, C.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Response to letter to the editor, Gilks et al
    Correspondence

    Weigelt, B.; Mueller, J. J.; Ellenson, L. H.; Abu-Rustum, N. R.; Aghajanian, C.
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
    Journal Article

    Pignata, S.; Bookman, M.; Sehouli, J.; Miller, A.; Penson, R. T.; Taskiran, C.; Anderson, C.; Hietanen, S.; Myers, T.; Madry, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator's choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy
    Meeting Abstract

    Lacuna, K. P.; Mandrekar, S. J.; Allred, J. B.; Berg, S. A.; Hensley, M. L.; Van Tine, B. A.; George, S.; Schwartz, G. K.; Ingham, M.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma
    Meeting Abstract

    Vergote, I.; Mirza, M. R.; Coleman, R. L.; Perez-Fidalgo, J. A.; Monk, B. J.; Valabrega, G.; Slomovitz, B. M.; Van Gorp, T.; Moore, K. N.; Sehouli, J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • CRI-CCTG-0003/IND.240: An immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC)
    Meeting Abstract

    Mackay, H.; Tinker, A.; Nelson, B.; Zamarin, D.; Odunsi, K.; Lheureux, S.; Ellard, S.; Smrke, A.; Gaudreau, P. O.; Faulkner, T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer
    Meeting Abstract

    Moore, K. N.; Bouberhan, S.; Hamilton, E. P.; Liu, J. F.; O'Cearbhaill, R. E.; O'Malley, D. M.; Papadamitriou, K.; Schröder, D.; Van N., Els; Yoo, S. Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade serous ovarian cancer (HGSOC)
    Meeting Abstract

    Hays, J. L.; Friedman, C. F.; Lakhani, N.; Anderson, C. K.; Buscema, J.; Duska, L. R.; Hamilton, E. P.; Taylor, S. E.; Carrington, C.; Burger, R. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save